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in a phase 3 trial. A follow-up study should preferably 
be done in a global setting and should include a larger 
proportion of non-HBV-infected patients with an age-
range similar to that  in other clinical trials involving 
patients with HCC.
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The global burden of gastro-oesophageal reflux disease: 
more than just heartburn and regurgitation
Gastro-oesophageal reflux disease is a common 
condition caused by the reflux of stomach contents into 
the oesophagus, leading to uncomfortable symptoms 
and complications.1,2 The prevalence of this disorder 
is increasing and this increase has been linked to 
population ageing and the obesity epidemic worldwide.1 
As these trends continue, especially in countries such as 
India and China, we need to consider their impact on the 
global burden of gastro-oesophageal reflux disease.
In The Lancet Gastroenterology & Hepatology, the GBD 
2017 Gastro-oesophageal Reflux Disease Collaborators 
used data from the Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD) 2017 and applied 
statistical tools that incorporate predictive covariates 
and adjustments for differences in study design to 
assess the global burden of gastro-oesophageal reflux 
disease.3 The global age-standardised prevalence 
of gastro-oesophageal reflux disease was stable 
over time, at 8791 (95% UI 7772–9834) cases per 
100 000 population in 1990 and 8819 (7781–9863) 
cases per 100 000 population in 2017, and the disease was 
responsible for an estimated 0·7% (95% UI 0·4–1·1) of all 
years lived with disability globally in 2017. Furthermore, 
although the age-standardised prevalence appeared to 
be stable between 1990 and 2017, all-age prevalence 
increased by 18·1% between 1990 and 2017, while years 
lived with disability increased by 67·1% between 1990 
and 2017, reflecting the increased prevalence in older age 
groups and population ageing over time.
As with any such analysis, the results depend on the 
quality of data and assumptions made by the authors 
about the disease. In this study the prevalence of gastro-
oesophageal reflux disease was defined by the presence 
or absence of typical reflux symptoms, specifically 
heartburn and acid regurgitation. However, there is an 
important difference between symptoms (which are 
based on a subjective description), and disease (diagnosis 
of which is based on objective evidence of reflux).
Patients with typical symptoms and reflux 
oesophagitis or Barrett’s oesophagus on endoscopy 
have gastro-oesophageal reflux disease; however, 
about half of patients with pathological acid exposure 
in the oesophagus do not have mucosal disease 
(ie, non-erosive reflux disease). Ambulatory reflux 
monitoring also identifies individuals with symptoms 
related to reflux events that have normal levels of acid 
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exposure (reflux hypersensitivity). All three groups 
are classified as forms of gastro-oesophageal reflux 
disease; however, the same symptoms are reported by 
individuals with functional heartburn in whom there 
is no pathological reflux and no association of reflux 
events with symptoms.4,5 Additionally, typical reflux 
symptoms can be reported by patients with other 
conditions including eosinophilic oesophagitis, motility 
disorders (eg, achalasia), and other functional disorders 
(eg, rumination). The prospective Diamond study 
showed that, for gastroenterologists, the sensitivity 
of symptom-based diagnosis of gastro-oesophageal 
reflux disease compared to objective pH studies was only 
67%, and specificity was 70%, with no improvement if 
a validated questionnaire was applied.6 Furthermore, 
symptom response to proton pump inhibitor therapy 
was neither sensitive nor specific to the diagnosis.6
Conversely, not all patients with pathological acid 
exposure complain of typical symptoms. Up to a third of 
individuals with Barrett’s oesophagus are asymptomatic, 
probably because metaplastic columnar mucosa has 
reduced sensitivity to acid.7 In other patients, gastro-
oesophageal reflux disease presents with non-cardiac 
chest pain or laryngo-pharyngeal complaints (eg, chronic 
cough or hoarseness).7,8 Atypical symptoms are less often 
triggered by reflux events (approximately 25% compared 
to approximately 50%). Nonetheless, excluding these 
presentations will systematically underestimate the 
burden of gastro-oesophageal reflux disease.
These findings make it clear that clinical history and 
response to therapy are insufficient to identify this 
condition. An international working group published 
the Lyon Classification, an approach to diagnosis of 
gastro-oesophageal reflux disease that uses objective 
information from endoscopy and physiological 
investigation.5 Conclusive evidence for the diagnosis 
includes severe mucosal disease on endoscopy or 
oesophageal acid exposure time longer than 6% on 
ambulatory reflux studies (even where endoscopy 
is normal). When endoscopy and pH-impedance 
monitoring are inconclusive (ie, acid exposure 
time 4–6%), then supportive evidence including the 
presence of a positive reflux-symptom association or 
ineffective oesophageal motility on manometry add 
confidence to confirm or refute the diagnosis.
The present study confirms that the prevalence 
of reflux symptoms increases with age;9 however, 
age-standardised prevalence was stable over the past 
25 years. This implies that the increase in obesity 
during this time has had no effect on the risk of gastro-
oesophageal reflux disease, which seems unlikely in 
the face of consistent evidence to the contrary.1,2,9 The 
authors themselves question whether this result “is 
driven more by measurement error than underlying 
epidemiology”. One technical reason for this discrepancy 
is that bodyweight increases with age,10 making it 
difficult to detect independent effects of these variables 
in the model. Another confounding factor is that, at 
any given level of reflux severity, older patients are less 
likely to report symptoms,10 a pattern observed in many 
disorders.
Determining the burden of diseases in an ageing 
population is important in planning health-care 
services. This study provides up to date information 
about the prevalence of typical reflux symptoms and 
the level of disability that is associated with gastro-
oesophageal reflux disease; however, the results are 
conservative because the analysis did not include the 
full spectrum of symptoms and disease caused by 
this condition. Nevertheless, it will be of interest to 
compare results for gastro-oesophageal reflux disease 
against those for other common conditions that affect 
both young and old populations, in developed and 
developing regions worldwide.
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A global perspective on oesophageal cancer: two diseases in 
one
Oesophageal cancer represents the sixth most common 
cause of cancer mortality worldwide.1 Underlying this 
cancer type are two distinct diseases characterised by 
different histologies: oesophageal adenocarcinoma and 
oesophageal squamous cell carcinoma.
Oesophageal adenocarcinoma predominately arises 
from Barrett’s oesophagus, with histological progression 
from metaplasia through to invasive carcinoma, and is 
typically localised to the distal oesophagus. The main 
risk factors are gastro-oesophageal reflux and obesity; 
high intake of red meat and low intake of fruits and 
vegetables are also associated with development of 
oesophageal adenocarcinoma. Oesophageal squamous 
cell carcinoma develops from squamous epithelial cells 
and is typically localised to the upper two-thirds of the 
oesophagus. Tobacco consumption and alcohol intake 
are the most notable risk factors, although their relative 
risk varies by region.
The GBD 2017 Oesophageal Cancer Collaborators 
used data from the Global Burden of Diseases, Injuries, 
and Risk Factors Study (GBD) 2017 dataset to provide 
a global overview of the distribution of oesophageal 
cancer and the morbidity, mortality, and key risk 
factors associated with the disease.2 They describe 
national trends in incidence between 1990 and 2017 
as well as the impact of risk factors on a regional level. 
Between 1990 and 2017, age-standardised incidence 
rates declined overall by 22·0% (95% uncertainty 
interval 18·6–25·2). This decline in age-standardised 
incidence was observed in all regions except for 
high-income North America (where oesophageal 
adenocarcinoma is predominant) and western sub-
Saharan Africa. At the country level, there was an 
association between a higher proportion of squamous 
cell carcinoma (out of all oesophageal cancer cases) 
and lower socioeconomic development. The global 
variation to a large extent recapitulates that seen from 
an analysis of data from the Global Cancer Observatory 
(GLOBOCAN) and Cancer Incidence in Five Continents, 
Volume X (CI5X).3
A major limitation of this analysis of GBD 2017 data, 
acknowledged by the authors, is the inability to clearly 
demarcate between oesophageal adenocarcinoma 
and oesophageal squamous cell carcinoma. Summary 
data on oesophageal cancer as a whole should not 
mask the differing global distribution, risk factors, and 
temporal changes occurring between the two diseases. 
Their distinct biology is reflected in their management 
approaches.
Although endoscopic management is appropriate 
for early-stage oesophageal squamous cell carcinoma 
and oesophageal adenocarcinoma, treatment patterns 
frequently diverge for later stages. For more locally 
advanced oesophageal cancer, survival outcomes with 
surgery alone are poor and a multimodal approach 
is recommended for patients who are deemed fit to 
undergo surgery. Oesophageal squamous cell carcinoma 
is more sensitive than oesophageal adenocarcinoma to 
radiotherapy, therefore definitive chemoradiotherapy 
is an option for patients with oesophageal squamous 
cell carcinoma, with equivalent survival outcomes 
but higher rates of local relapse necessitating salvage 
oesophagectomy. Alternatively, both oesophageal 
adeno carcinoma and oesophageal squamous cell carcin-
oma can be treated by either perioperative chemo-
therapy or neoadjuvant chemoradiotherapy followed 
by surgery, with treatment preferences varying globally 
depending on the region. Given the reduced sensitivity 
of oesophageal adenocarcinoma to radiotherapy, 
patients with oesophageal adenocarcinoma should 
proceed to surgery even after showing good response to 
neoadjuvant chemo radiotherapy.
